Research Watch: What Recent Studies Say About Supplements for Cardiovascular Health

Welcome to the first Research Watch. Every Saturday I read the recent supplement research that crossed my desk over the previous two weeks and write up the studies worth knowing about. No product push, no marketing angle. Just the studies, what they found, and what I think it means for someone trying to make informed choices. This week: what is the actual state of evidence for supplements and cardiovascular health.

Quick Answer

Recent meta-analyses give the strongest signal for cardiovascular benefit to omega-3 fatty acids, CoQ10 (specifically in heart failure), and magnesium plus vitamin D for blood pressure support. Vitamin D and omega-3 in healthy populations have more mixed findings for hard endpoints. The 2022 umbrella review of 884 randomized trials covering nearly 884,000 participants found moderate-to-high quality evidence that several micronutrients reduce cardiovascular risk, but the size of the effect varies considerably by population and baseline status. Supplements complement, not replace, the foundational interventions (diet, exercise, sleep, not smoking).

What This Week's Reading Covered

The cardiovascular supplement literature is large, contradictory, and easy to cherry-pick. To set a fair baseline, I started with the most rigorous source in this space: an umbrella review of micronutrient supplementation for cardiovascular outcomes published in the Journal of the American College of Cardiology in late 2022. It analyzed 884 randomized controlled trials covering 883,627 participants across dozens of supplements. From there I followed citation chains to the more recent (2024-2025) systematic reviews and meta-analyses on specific compounds.

The JACC Umbrella Review (the headline)

The 2022 umbrella review classified evidence quality across multiple cardiovascular micronutrients. The compounds with moderate-to-high quality evidence for reducing some cardiovascular risk markers were omega-3 fatty acids, folate, CoQ10, and certain combinations of B-vitamins. Vitamin D and selenium showed mixed signals depending on the outcome studied. Effect sizes were modest but clinically meaningful for the better-evidenced compounds.

The honest interpretation: this is the highest-quality summary of cardiovascular supplement evidence to date, and it does not support the breathless "this one supplement will save your heart" framing common in supplement marketing. It does support the case for specific compounds in specific contexts.

Source: Lacey B et al. JACC 2022. PubMed 36774873

CoQ10 in Heart Failure: The Strongest Single Signal

A 2024 meta-analysis of 33 randomized controlled trials on CoQ10 in heart failure patients reported a relative risk of 0.64 for all-cause mortality and 0.50 for heart failure hospitalizations versus placebo. Those are large effects for a supplement and align with multiple earlier analyses. The catch: the trials studied diagnosed heart failure patients on standard medical therapy, not healthy adults taking CoQ10 prophylactically.

What this means in practice: if you have diagnosed heart failure, talk to your cardiologist about whether CoQ10 should be part of your treatment. The signal is strong enough that it deserves a real conversation. If you are healthy, CoQ10 may have other benefits (mitochondrial support, particularly relevant if you take statins, which deplete CoQ10) but the heart-failure-mortality finding does not directly apply to you.

Source: Cao Y et al. 2024 meta-analysis. PMC 12883399

Magnesium, Calcium, and Vitamin D for Blood Pressure

A 2024 systematic review looked at the combined and individual effects of magnesium, calcium, and vitamin D supplementation on hypertension. Magnesium was the most consistent contributor to modest blood pressure reductions, with effect sizes large enough to be clinically relevant in people with elevated baseline blood pressure or magnesium insufficiency. Vitamin D's individual contribution was smaller and more dependent on baseline 25(OH)D status.

The practical version: if you have borderline-high blood pressure and your magnesium intake is low (most adults under-consume magnesium), an evidence-aligned daily dose of 200 to 400 mg of elemental magnesium has a real chance of contributing a modest reduction. Not a substitute for the bigger levers (diet pattern, sodium intake, exercise, weight), but a useful supporting input.

Source: 2024 systematic review. Springer link

VITAL: The Big Healthy-Adult Trial

VITAL (Vitamin D and Omega-3 Trial) randomized 25,871 healthy adults to vitamin D (2,000 IU/day) and/or marine omega-3 (1 g/day) and followed them for a median of 5.3 years. The headline finding: neither supplement significantly reduced the primary endpoint of major cardiovascular events in the general healthy population.

The nuanced finding: prespecified subgroup analyses showed reduced cardiovascular events with omega-3 in people with low fish intake, and reduced cancer mortality with vitamin D in normal-weight subgroups. The full pattern is "no average effect, real effects in specific subgroups."

What this means: blanket vitamin-D-and-fish-oil-for-everyone is not supported as cardiovascular prevention in healthy adults. Targeted supplementation in people with low dietary intake or measured insufficiency is more defensible.

Source: Manson JE et al. NEJM 2019. PubMed 30415629

REDUCE-IT: The High-Dose EPA Outlier

REDUCE-IT is the trial that complicates the omega-3 story. It enrolled 8,179 adults with elevated cardiovascular risk and high triglycerides, randomized them to a prescription-grade high-dose EPA formulation (4 g/day of icosapent ethyl) or placebo, and followed them for a median of 4.9 years. The intervention group had a 25 percent relative reduction in major cardiovascular events.

The reason this matters: most general-population omega-3 trials use lower doses of mixed EPA/DHA fish oil and find smaller or null effects. REDUCE-IT suggests that dose and formulation matter significantly. A 1,000 mg fish oil capsule is not the same intervention as 4,000 mg of prescription EPA in high-risk patients. The studies are not comparable.

Important caveat: a follow-up trial (STRENGTH) with a different omega-3 formulation did not show the same benefit. The mineral oil placebo used in REDUCE-IT has been questioned. The cardiovascular community is not fully settled on what to make of all this.

Source: Bhatt DL et al. NEJM 2019. PubMed 30415628

What This Means for You

Reading across all five studies, the honest summary is this:

• For healthy adults with no diagnosed cardiovascular risk: the marginal benefit of supplements is small. The big levers are still dietary pattern (Mediterranean-style remains the most-evidenced approach), exercise, sleep, weight management, and not smoking. Magnesium and omega-3 may add a small positive contribution if your dietary intake is low.
• For people with elevated cardiovascular risk markers: the case for omega-3 (particularly higher-dose EPA), magnesium for blood pressure, and CoQ10 for heart-failure-adjacent indications is stronger. This is the population where the trials show the largest effects.
• For everyone: supplements are inputs, not interventions. They do their best work as one variable in a system of healthy daily inputs, not as a substitute for any of the foundations.

What I Did Not Cover This Week

This was an intentionally narrow look at the highest-quality cardiovascular evidence. I did not get into the popular supplement-influencer space (TRT-adjacent compounds, exotic adaptogens, peptides). The reason is that those compounds either don't yet have the trial data to evaluate at this level or they fall outside the supplement category entirely. We will get to them in future weeks as the evidence base develops.

This article is for informational purposes and is not medical advice. Cardiovascular health is complex and individual. Always consult a qualified healthcare practitioner before adding any supplement, especially if you take prescription medication, have a diagnosed cardiovascular condition, or are at elevated risk.

Sources

1. Lacey B et al. Umbrella review of micronutrient supplementation and cardiovascular outcomes. J Am Coll Cardiol. 2022.
2. Cao Y et al. Coenzyme Q10 supplementation in heart failure: meta-analysis of 33 RCTs. PMC12883399, 2024.
3. 2024 systematic review of magnesium, calcium, and vitamin D in hypertension management. Springer / BMC Complementary Medicine and Therapies, 2024.
4. Manson JE et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer (VITAL trial). N Engl J Med. 2019;380:23-32.
5. Bhatt DL et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380:11-22.